5 Companies Looking to Profit From Cannabis Legalization

5 Companies Looking to Profit From Cannabis Legalization

PR Newswire

LONDON, May 15, 2018

LONDON, May 15, 2018 /PRNewswire/ --

FN Media Group Presents OilPrice.com News Commentary 

The marijuana market is poised to see the biggest investor bull rush of the 21st century. In the U.S. alone, the marijuana market is set to reach $25 billion by 2020 with recreational use being legal in a growing number of states. The Canadian recreational market is forecast to hit $8 billion. Federal legislation of cannabis throughout Canada is scheduled to be signed into law by the end of Summer 2018. Mentioned in today's commentary includes: Scotts Miracle-Gro (NYSE:SMG), Aurora Cannabis Inc (TSX:ACB) (OTC:ACBFF), Cronos Group Inc (NASDAQ:CRON), Emerald Health Therapeutics Inc (TSX-V:EMH) (OTC:EMHTF), OrganiGram Holdings. (TSX-V:OGI) (OTC:OGRMF).

Unsurprisingly, the legalization of this enormous market has already brought investors incredible returns - with the twelve largest companies seeing an average gain of 332 percent over the course of a year, July 2016 to July 2017. The biggest question facing investors in 2018 is how to identify those companies with the most exposure to these gains.

With all of that in mind, here are 5 companies to watch in 2018:

#1 Canopy Growth Corp. -WEED, TWMJF

With a market cap of $4.35 billion, Canopy Growth Corp. has taken off like a rocket, with a stock price that has tripled since July 2017. In February 2018, Canopy completed a CA$200 million (US$155.0 million) offering co-led by Bank of Montreal, the first time a large Canadian bank offered equity financing for a cannabis company.

As a result of this growth, Canopy Growth Corp. became the first Cannabis company to be added to the S&P/TSX Composite Index. With its reputation as 'the biggest weed producer in the world', investors may look to Canopy Growth as one of the safer names in the space.

#2 Cannabis Wheaton (CBW; CBWTF)

For investors interested in gaining exposure to the entire North American market, Cannabis Wheaton is a company unlike any other. This innovative company is doing what streaming and royalty companies have done for the mining industry and what Netflix has done for movies - Cannabis Wheaton is streaming pot.

As demand soars and companies attempt to get in on the biggest bull run of cannabis products, Cannabis Wheaton is providing a route to the full spectrum of the industry for new and existing partners. It is a streaming-based business that is entirely new to a market that is forecast to explode in demand.

This business model removes the risks associated with betting on a single producer, instead giving access to a much larger portion of the industry. And the team putting those deals together is made up of some of the biggest names in the space.

This one-of-a-kind company has already lined up 15 partners, with 17 facilities-for 2.0 million effective square feet of growing acreage. In return, they get minority equity interests and a portion of the pot produced.

With its streaming partners in place, Cannabis Wheaton partners are getting set to ramp up production to meet expected runaway demand once legalization goes through. The company anticipates a seller's market for pot until 2021- where demand will outstrip supply for the next three years at least.

To boost production, Cannabis Wheaton has made a raft of new investments. It acquired Dosecann Inc., a licensed dealer with a 42,000 square foot facility on Prince Edward Island. Last year, it bought out RockGarden, another licensed producer. More recently, it purchased Robinson's Cannabis Inc., a company planning to produce recreational cannabis that is close to completing a 27,000 square foot cultivation facility in Nova Scotia. With these new assets and what are expected to be low production costs, Cannabis Wheaton expects revenue to dramatically increase once the bulk of their projects come online in 2019

#3 Sanofi - SNY

Sanofi is a French-based giant, with a current market cap of over $109 billion. Even though the company beat its Q1 earnings estimates, its stock has been falling for the last six months. This gives investors an opportunity to buy in before the pharma giant gets into the cannabis game.

Sanofi is already working with cannabinoids, marketing Rimonabant - a drug designed to control appetite. It is already scouring the market for a late stage medical marijuana company.

2018 is going to be the year that big pharma makes its move, as recreational marijuana sends the medical space into overdrive and the late stage developments become ripe for a buyout. These giants won't be competing with medical marijuana companies, they will own them.

#4 Pfizer -PFE

Pfizer is another big pharma pick and boasts some sizzling dividends for investors as well as a very solid growth picture over the past five years. Its two segments, innovative health and essential health, generated $52.8 billion in revenue last year, with net income of $7.2 billion.

In 2018, Pfizer expects its best-selling drugs to continue to grow. That's good news for a company that began to lose revenue after it lost patent protection on the hugely popular drug Lipitor in 2011. New drugs like Eliquis and Xeljanz will began contributing to the company's coffers in 2018.

It is in this new product segment that we will be seeing cannabis breakthroughs and with a market cap of over $215 billion, Pfizer has the influence to bring in winning deals. Pfizer has also been searching for an MA opportunity that will bring new products under its umbrellas-and the timing could be perfect for it to acquire a cannabis firm.

#5 Scotts Miracle-Gro (NYSE:SMG)

Scotts Miracle-Gro is a 'pick and shovel' company for the marijuana industry and is yet another way investors can look to play the boom. This is a company which has seen some hard times this year-the price tumbled more than 20 percent in a single day, falling from $107 to $82/share in the space of a few months.

Despite this drop, the company has emerged in a stronger position and is uniquely positioned to take advantage of the cannabis boom-in fact, it might have more exposure to cannabis than any other major firm.

SMG is also looking to get leaner and meaner-it plans to cut back on labor costs and save $35 million from hydroponics, making more from less each year.

Other significant players tapping into the global marijuana market:

Aurora Cannabis Inc (TSX:ACB) (OTC:ACBFF) which is a producer and distributer of medical marijuana across Canada. In the marijuana industry, patients will often have to jump through hoops to procure their medication, but with Aurora's caring and knowledgeable staff, patients no longer have to worry.

Emerald Health Therapeutics Inc (TSXV:EMH) (OTC:EMHTF) is another producer and distributer of medical marijuana. Based in British Columbia, Emerald Health is fully licensed by Access to Cannabis for Medical Purposes Regulations (ACMPR) and provides high quality medicine of different varieties.

Cronos Group Inc (NASDAQ:CRON) is another Toronto-based cannabis company with a lot of ambition. The company has prioritized its production acquisitions in order to provide geographically. The company typically invests in companies based in Canada and is primarily an equity investor, which may also advance debt as appropriate.

OrganiGram Holdings. (TSXV:OGI) (OTC:OGRMF): Organigram Inc. is a licensed medical marijuana producer in Canada, while it managed to maintain its production license this year, the company saw its stock price fall somewhat Year-To-Date, but we see strong upside for this stock as the changing Canadian cannabis legislation could give a massive boost to the market.

By. Meredith Taylor

**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

FORWARD-LOOKING STATEMENT. Statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Forward looking statements in this article include: that the Canadian government will fully legalize and regulate cannabis this year; that the Canadian medical and recreational markets combined will be worth $8 billion in gross sales in the year after legalization; that Cannabis Wheaton Income Corp. ("Cannabis Wheaton") can raise funds and partner quickly with new firms looking to get into the Cannabis industry and access the expertise of Cannabis Wheaton's management team and non-dilutive capital; that there will likely be a supply shortage; that, if cannabis markets open up in other industrialized countries, the global cannabis market could expand exponentially; That Cannabis Wheaton's production costs will be low. Forward-looking information is based on the opinions and estimates of Cannabis Wheaton at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Forward looking statements involve known and unknown risks and uncertainties which may not prove to be accurate. Actual results and outcomes may differ materially from what is expressed or forecasted in these forward-looking statements. Matters that may affect the outcome of these forward looking statements include: that Cannabis may not be legalized on the timeline as expected or at all; that markets may not materialize as expected; that cannabis may not turn out to have as large a market as thought or be as lucrative as thought as a result of competition or other factors; that Cannabis Wheaton may not be as able to diversify or scale up as thought because of potential lack of capital, lack of facilities, regulatory compliance requirements in Canada or outside of Canada or lack of suitable employees, partners or suppliers; that Cannabis Wheaton may not be able to raise funds and offer better conditions to potential partners than competitors in the cannabis industry; that partners of Cannabis Wheaton may not be granted licenses or additional capacity under existing or newly applied for licenses for them to grow for the cannabis market; that foreign governments may not allow Cannabis Wheaton to operate in their countries; that actual operating performance of the facilities affiliated with Cannabis Wheaton do not meet expectations; that competition quickly develops; that Cannabis Wheaton may not be able to retain key employees, partners and suppliers; costs may be higher than expected and profits therefore lower; competitors may capture most or all of the increased market demand; and other risks affecting the Company in particular and the cannabis industry generally, including without limitation risks related to most agricultural crops, including crop failure. The forward-looking statements in this document are made as of the date hereof and the Company disclaims any intent or obligation to update such forward-looking statements except as required by applicable securities laws.

DISCLAIMERS

PAID ADVERTISEMENT.


PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, and their owners, managers, employees, and assigns (collectively, "we" or the "Company") has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Cannabis Wheaton seventy-five thousand US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:


This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by Cannabis Wheaton to conduct investor awareness advertising and marketing for [CBW and CBWTF]. Oilprice.com receives financial compensation to promote public companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.

SHARE OWNERSHIP. The owner of Oilprice.com owns shares of this featured company and therefore has an additional incentive to see the featured company's stock perform well. The owner of Oilprice.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of Oilprice.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LEGAL ADVISORY. Investing in companies associated with the cannabis industry may be illegal in the jurisdiction where a reader resides. Before investing in any public company involved in the cannabis industry, potential investors should check with their legal advisor as to whether an investment will breach local or federal law.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.


TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://oilprice.com/terms-and-conditions If you do not agree to the Terms of Use http://oilprice.com/terms-and-conditions,  please contact Oilprice.com to discontinue receiving future communications.

DISCLAIMER: OilPrice.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with OilPrice.com or any company mentioned herein. The commentary, views and opinions expressed in this release by OilPrice.com are solely those of OilPrice.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

 

Contact Information:
editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611


Voltar noticias em Inglês